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CI, 0.68 to 1.13, P 5 NS) at baseline, three months, and sixComparative mortality of hemodialysis and peritoneal dialysis
months. There was no survival advantage for either modalityin Canada.
in any of the major subgroups defined by age, sex, or diabeticBackground. Comparisons of mortality rates in patients on
status.hemodialysis versus those on peritoneal dialysis have been
Conclusions. The apparent survival advantage of peritonealinconsistent. We hypothesized that comorbidity has an impor-
dialysis in Canada is due to lower comorbidity and a lowertant effect on differential survival in these two groups of pa-
burden of acute onset end-stage renal disease at the inceptiontients.
of dialysis therapy. Hemodialysis and peritoneal dialysis, asMethods. Eight hundred twenty-two consecutive patients at
practiced in Canada in the 1990s, are associated with similar11 Canadian institutions with irreversible renal failure had an
overall survival rates.extensive assessment of comorbid illness collected prospec-
tively, immediately prior to starting dialysis therapy. The co-
hort was assembled between March 1993 and November 1994;
vital status was ascertained as of January 1, 1998. In current clinical practice, there are two major modal-Results. The mean follow-up was 24 months. Thirty-four
ities of dialysis available, hemodialysis and peritonealpercent of patients at baseline, 50% at three months, and 51%
dialysis, which are very different in terms of techniqueat six months used peritoneal dialysis. Values for a previously
validated comorbidity score were higher for patients on hemo- and physiology. Although one modality is frequently
dialysis at baseline (4.0 vs. 3.1, P , 0.001), three months (3.7 preferable to another in terms of an individual patient’s
vs. 3.2, P 5 0.001), and six months (3.6 vs. 3.2, P 5 0.005). abilities, medical problems, or geographic location, con-The overall mortality was 41%. The unadjusted peritoneal
troversy still exists regarding which treatment, if either,dialysis/hemodialysis mortality hazard ratios were 0.65 (95%
results in greater patient survival times. Studies compar-CI, 0.51 to 0.83, P 5 0.0005), 0.84 (95% CI, 0.66 to 1.06, P 5
NS), and 0.83 (95% CI, 0.64 to 1.08, P 5 NS) based on the ing mortality rates to date have shown markedly incon-
modality of dialysis in use at baseline, three months, and six sistent results [1–15]. It is plausible that unmeasured
months, respectively. When adjusted for age, sex, diabetes, differences in case mix could account for discordant con-cardiac failure, myocardial infarction, peripheral vascular dis-
clusions from different studies. The quality of comorbid-ease, malignancy, and acuity of renal failure, the corresponding
ity has differed in previous studies. Ideally, such datahazard ratios were 0.79 (95% CI, 0.62 to 1.01, P 5 NS), 1.00
(95% CI, 0.78 to 1.28, P 5 NS), and 0.95 (95% CI, 0.73 to should be extensive and collected prospectively. A ran-
1.24, P 5 NS). Adjustment for a previously validated comorbid- domized trial of these two dialysis modalities will be
ity score resulted in hazard ratios of 0.74 (95% CI, 0.58 to 0.94, very difficult, given the ethical and logistic problemsP 5 0.01), 0.94 (95% CI, 0.74 to 1.19, P 5 NS), and 0.88 (95%
associated with such a study. Longitudinal epidemiologic
studies with comprehensive comorbidity data remain the
most feasible way to determine whether these two treat-Key words: dialysis mortality, hemodialysis, peritoneal dialysis, comor-
bidity, end-stage renal disease. ments differ in terms of patient outcomes.
In a previous study, we developed a scoring systemReceived for publication April 12, 1999
based on age and comorbidity present at the onset ofand in revised form November 10, 1999
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scoring system was further evaluated with respect to its These comorbidity data were used to calculate a prog-
nostic score derived from a previous study of patientsability to predict death within six months of starting
dialysis in a separate prospective, multicenter, observa- starting maintenance dialysis therapy [16]. This score
incorporated an individual patient’s age, the presencetional study of 822 patients [17]. In this study, each pa-
tient had a detailed assessment of comorbid illness imme- and/or severity of cardiac failure, coronary artery disease,
arrhythmia, peripheral vascular disease, malignancy,diately prior to his or her first dialysis treatment and was
followed until death or for six months. We hypothesized coma, shock, severe liver disease, and requirement for
mechanical ventilation. The resultant score could rangethat comorbidity has an important effect on differences
in survival of peritoneal dialysis and hemodialysis pa- from 1 to 22, with higher values reflecting a higher burden
of comorbid illness.tients; given the extent of comorbidity data available,
this cohort represented an opportunity to study the effect In addition to the first mode of dialysis to be used for
each patient, documentation was made of the date ofof concurrent illness on the relative long-term survival
of peritoneal dialysis and hemodialysis patients. We any switch or switches in mode of dialysis that each
patient underwent. Data regarding dialysis techniquetherefore extended the follow-up duration and, in this
article, report the impact of comorbidity on differential were gathered retrospectively. Each patient’s chart was
reviewed, and the modality of dialysis at baseline and atsurvival in these two groups of patients.
subsequent three-month intervals was ascertained and
recorded. Because the primary objective of the original
METHODS
study was to assess the effect of comorbidity on survival
Patients of patients with end-stage renal disease, data pertaining
to the dose of dialysis were not systematically recordedThis prospective study used a cohort of patients with
end-stage renal disease originally assembled for a study as part of the study protocol. However, in most cases,
the number of hours per week of dialysis for those pa-regarding prediction of early death for patients starting
dialysis treatment [17]. The cohort was assembled be- tients on hemodialysis and the volume of dialysate used
per day by peritoneal dialysis patients was available.tween March 1993 and November 1994. Consecutive pa-
tients with renal failure of any cause that was considered Documentation was made of date of death, renal trans-
plantation, recovery of loss of renal function, or loss toirreversible and who started dialysis at any of 11 partici-
pating Canadian centers were entered into the study. follow-up as of January 1, 1998.
These centers were all university affiliated and were lo-
Analysiscated in the following Canadian cities: St. John’s, Halifax,
Saint John, Montreal, Toronto, London, Winnipeg, Cal- Two methods of survival analyses were employed. Cox
proportional hazards regression, an intention-to-treatgary, Edmonton, and Vancouver.
This study was approved by the research ethics board form of analysis, was used to adjust the peritoneal dial-
ysis/hemodialysis hazard ratios of mortality for age, gen-at each of the participating institutions.
der, diabetic status, cardiac failure, myocardial infarc-
Data collection tion, peripheral vascular disease, malignancy, acuity of
onset, and the total comorbidity score [18]. Survival wasAt the time of enrollment into the study, a detailed
description of each patient’s diagnosis and clinical status compared in three separate time frames. Patients were
assigned to either hemodialysis or peritoneal dialysiswas recorded on a standard form. The following data
were collected at study entry: initial mode of dialysis (he- treatment groups according to the mode of dialysis in
use at baseline, as well as three and six months aftermodialysis or peritoneal dialysis), date of first dialysis for
end-stage renal disease, original renal disease, pattern of entry into the study if they survived to these points.
This design was chosen because (1) peritoneal dialysisonset of renal failure (acute, acute-on-chronic, or chronic),
age, sex, race, presence and duration of diabetes, pres- patients frequently have a brief course of hemodialysis
while waiting for catheter placement, training, etc., andence of a treated arrhythmia, presence or history of an-
gina, presence or history of myocardial infarction, pres- (2) acute indications for dialysis are preferentially
treated with hemodialysis. We also used Poisson regres-ence or history of congestive heart failure, presence or
history of peripheral vascular disease, presence of chronic sion, a method that deals with treatment switches by
incorporating the person-time that individual patientslung disease, presence of coma or severe cerebral dis-
ease, presence of severe liver disease, presence of malig- contribute to each treatment group, to adjust for these
same variables [19]. For this analysis, the mode of dialysisnancy, blood dyscrasia, or myeloma, serum albumin,
height, weight, clinical impression of malnutrition, pres- in use was determined at three-month intervals begin-
ning with the first treatment received. Again, three sepa-ence of systemic sepsis, presence of shock, and need for
ventilatory support. The definitions for each of these rate start points for the analysis were used: baseline,
three months, and six months. In both types of analyses,variables have been previously published in detail [17].
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Table 1. Cohort characteristics at study entry according to first modality of dialysis used
Peritoneal dialysis
Variable Hemodialysis (N 5 540) (N 5 282) P value
% Male 58.7 59.9 NS
% Caucasian 78.9 81.4 NS
% Acute or acute-on-chronic onset 24.8 7.9 ,0.001
% Diabetes 35.9 36.9 NS
% Cardiac failure 39.3 26.5 ,0.001
% Myocardial infarction 19.6 14.0 0.05
% Peripheral vascular disease 18.0 13.3 NS
% Malignancy 4.3 2.5 NS
% Dysrhythmia 9.3 3.2 0.003
Age 59.4 (58.1–60.7) 56.1 (54.2–58.0) 0.004
Body mass index 25.6 (25.1–26.1) 25.0 (24.4–25.6) NS
Albumin 33.6 (33.1–34.1) 35.0 (34.3–35.7) 0.004
Hemoglobin 88.7 (87.4–90.0) 92.3 (90.4–94.2) 0.003
Diastolic blood pressure 78.7 (77.4–80.0) 80.1 (78.6–81.6) NS
Systolic blood pressure 147.4 (145–150) 145.1 (142–148) NS
Total comorbidity scorea 4.0 (3.78–4.22) 3.1 (2.87–3.33) ,0.001
Etiology of renal failure (%)
Glomerulonephritis 18.9 18.3 reference
Diabetes 27.8 31.5 NS
Hypertension 15.7 13.6 NS
Reno-vascular 6.3 4.3 NS
Interstitial disease 1.5 3.6 NS
Polycystic kidney 3.9 8.2 0.009
Other 17.0 11.1 0.02
Unknown 8.9 9.0 NS
Parentheses indicate 95% CI.
NS is not statistically significant.
a Score based on age, requirement for mechanical ventilation, presence and/or severity of cardiac failure, ischemic heart disease, arrhythmia, peripheral vascular
disease, malignancy, coma, severe liver disease, or shock (discussed in the text)
patients were censored at the time of renal transplanta-
tion or on reaching the time of final follow-up on dialysis
therapy.
Baseline descriptors are presented as mean values with
95% confidence intervals or as percentages. Normally
distributed continuous variables were compared using
analysis of variance. Categorical variables were com-
pared using x2 analysis. All statistical tests are two-tailed,
with a P value of less than 0.05 taken to indicate statistical
significance.
Fig. 1. Co-morbidity score values for patients on peritoneal dialysis
( ) versus hemodialysis (h) according to the modality in use at base-
line, three months, and six months. Vertical bars indicate 95% CI.RESULTS
Patient and treatment characteristics
Eight hundred twenty-two patients were enrolled in
ure, and arrhythmia. The spectrum of original cause ofthe study. Peritoneal dialysis was used by 34% of patients
renal failure was similar in both groups of patients atat baseline, 50% at three months, and 51% at six months.
baseline, although a higher proportion of peritoneal dial-The mean follow-up was 24.0 (95% CI, 22.8 to 25.2)
ysis patients had polycystic kidney disease (8.2 vs. 3.9%,months, with a maximum follow-up time of 56.1 months.
P 5 0.009), and more hemodialysis patients had theirTable 1 indicates the cohort characteristics at study
etiology classified as “other” (17.0 vs. 11.1%, P 5 0.02).entry according to the initial mode of dialysis therapy.
The total comorbidity score was significantly higherAt baseline, patients on hemodialysis differed from those
in hemodialysis compared with peritoneal dialysis pa-on peritoneal dialysis with respect to age, initial hemo-
tients at baseline (4.0, 95% CI, 3.8 to 4.2 vs. 3.1, 95%globin, and serum albumin. Differences were present in
CI, 2.9 to 3.3, P , 0.001), three months (3.7, 95% CI,the proportion of patients with acute or acute-on-chronic
onset of renal failure, myocardial infarction, cardiac fail- 3.5 to 3.9 vs. 3.2, 95% CI, 3.0 to 3.4, P 5 0.001), and six
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Table 2. Principal outcomes according to modality of dialysis used at baseline, 3, and 6 months
Baseline Month 3 Month 6
Outcome HD (N 5 540) PD (N 5 282) HD (N 5 351) PD (N 5 354) HD (N 5 314) PD (N 5 325)
Death 248 (45.9%) 93 (33.3%) 145 (41.3%) 126 (35.6%) 125 (39.8%) 110 (33.8%)
P 50.001 NS NS
Renal transplant 112 (20.7%) 86 (30.8%) 77 (21.9%) 105 (29.7%) 70 (22.3%) 91 (28.0%)
P 50.002 50.02 NS
Switch of therapy 137 (25.4%)a 87 (31.9%)a 33 (9.4%)b 106 (29.9%)b 24 (7.6%)c 93 (28.6%)c
P NS ,0.001 ,0.001
Abbreviations are: HD, hemodialysis; PD, peritoneal dialysis; NS, difference not statistically significant.
a Anytime after starting therapy
b After 3 months
c After 6 months
Table 3. Mortality hazard ratios, adjusted with proportional hazards analysis (95% CI)
Factor Baseline Month 3 Month 6
Peritoneal dialysis vs. hemodialysis 0.79 (0.62–1.01) 1.00 (0.78–1.28) 0.95 (0.73–1.24)
NS, x2 52.93 NS, x2 50.0002 NS, x2 50.13
Age per year 1.04 (1.03–1.05) 1.02 (1.02–1.04) 1.03 (0.93–1.84)
P,0.00001, x2 552.11 P,0.00001, x2 536.75 P,0.00001, x2 531.94
Male gender 1.04 (0.81–1.29) 1.0 (0.78–1.30) 1.05 (0.81–1.40)
NS, x2 50.03 NS, x2 50.004 NS, x2 50.21
Acute onset 1.54 (1.18–2.02) 1.55 (1.15–2.10) 1.31 (0.93–1.84)
P50.002, x2 59.96 P50.005, x2 58.06 NS, x2 52.42
Diabetes 1.38 (1.09–1.75) 1.57 (1.21–2.03) 1.72 (1.31–2.27)
P50.008, x2 57.14 P50.0006, x2 511.80 P50.0001, x2 514.97
Cardiac failure 1.47 (1.16–1.87) 1.34 (1.03–1.74) 1.35 (1.02–1.78)
P50.002, x2 510.11 P50.03, x2 54.83 P50.04, x2 54.33
Myocardial infarction 1.02 (0.77–1.34) 1.16 (0.86–1.57) 1.25 (0.91–1.72)
NS, x2 50.01 NS, x2 50.97 NS, x2 51.89
Peripheral vascular disease 1.57 (1.21–2.05) 1.37 (1.01–1.85) 1.22 (0.73–1.24)
P50.0007, x2 511.38 P50.04, x2 54.22 NS, x2 51.35
Malignancy 2.16 (1.32–3.55) 2.00 (1.09–3.69) 1.90 (0.73–1.24)
P50.002, x2 59.35 P50.03, x2 54.94 P50.06, x2 53.48
Total x2 156.48 100.34 83.33
Note: Results represent three separate analyses, with treatment groups defined by modality of dialysis in use at baseline, 3, and 6 months. NS is difference not
statistically significant.
months (3.6, 95% CI, 3.4 to 3.8 vs. 3.2, 95% CI, 3.0 to tion within the study period. Table 2 indicates the princi-
pal outcomes according to the mode of dialysis in use3.4, P 5 0.005; Fig. 1).
For peritoneal dialysis patients at baseline, the mean at baseline, three months, and six months. In the groups
defined by the first dialysis modality used, mortality wasvolume of dialysis solution used per day was 8.0 L/day
(95% CI, 7.6 to 8.4 L/day, N 5 174); for hemodialysis higher in hemodialysis patients than in peritoneal dialysis
patients (45.9 vs. 33.3%, P 5 0.001). Mortality was simi-patients, the mean number of hours per week of treat-
ment was 10.1 h/week (95% CI, 9.9 to 10.3 h/week, N 5 lar in the groups defined by the mode of dialysis used
by those patients still alive at three months (hemodialysis421). At three months, the mean volume of dialysis solu-
tion used per day by peritoneal dialysis patients was 8.3 41.3% vs. peritoneal dialysis 35.6%, P 5 NS) or six
months (hemodialysis 39.8% vs. peritoneal dialysisL/day (95% CI, 8.1 to 8.5 l/day, N 5 294), and hemodialy-
sis patients received a mean of 10.5 h/week (95% CI, 33.8%, P 5 NS). Analysis of the cause of death showed
no differences between hemodialysis and peritoneal dial-10.3 to 10.7 h/week, N 5 280) of dialysis. At six months,
patients on peritoneal dialysis used 8.5 L/day of dialysis ysis patients at baseline, three months, or six months.
Table 3 shows mortality hazard ratios adjusted usingsolution (95% CI, 8.2 to 8.8 L/day, N 5 261), and hemodi-
alysis patients received 10.5 h/week of dialysis (95% CI Cox proportional hazards regression. Three different
analyses were performed, defining treatment groups ac-10.3 to 10.7 h/week, N 5 221).
cording the mode of dialysis each patient was on at base-
Outcomes line, three months, and six months. Age, diabetes, and
cardiac failure were significant independent risk factorsOverall mortality was 41%. Twenty-four percent of
the patients in the cohort underwent renal transplanta- for death at each time point. Acuity of onset of renal
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tients who were on hemodialysis at three and six months
were less likely to undergo a switch in their treatment
in the future than patients on peritoneal dialysis (9.4 vs.
29.9, P , 0.001 at 3 months, 7.6 vs. 28.6%, P , 0.001 at
6 months).
Mortality rate ratios from Poisson regression modeling
are shown in Table 4. Three separate analyses were per-
formed, with the start point for the model set at baseline,
three months, and six months. The impact of the various
comorbid conditions on the risk of death was unchanged
from the previous analysis. Again, the peritoneal dialysis/
hemodialysis mortality rate ratios were not statistically
different than one at all three time points, indicating no
difference in survival between the two groups.
DISCUSSION
In this inception cohort of Canadian dialysis patients,
Fig. 2. Peritoneal dialysis/hemodialysis hazard ratios derived from pro-
comorbidity-adjusted survival was similar in patientsportional hazards model according to mode of dialysis used at baseline,
three months, and six months with 95% CI. Symbols are: (h) unadjusted; treated with hemodialysis and peritoneal dialysis. Pa-
(j) adjusted for age, sex, acuity of onset, diabetes, myocardial infarction, tients initially treated with hemodialysis had a higher
cardiac failure, malignancy, and peripheral vascular disease; (d) ad-
burden of comorbid illness, as well as a higher incidencejusted for comorbidity score only.
of acute onset of renal failure compared with those on
peritoneal dialysis. When comorbidity was taken in ac-
count, there was no survival advantage associated with
failure, peripheral vascular disease, and malignancy were either therapy.
highly significant predictors of death at baseline, but Two different methods of adjusting for comorbidity
their effect lessened in subsequent time periods. The were employed in separate analyses: a total comorbidity
peritoneal dialysis/hemodialysis mortality ratios were score based on a previously validated system and adjust-
not statistically different from 1 at baseline, three months, ment for the presence individual comorbid conditions,
and six months, indicating no covariable adjusted sur- age, and acuity of onset of renal failure. Results obtained
vival advantage for either modality of treatment. in both analyses were similar, although the comorbidity
In addition to the comorbidity adjustment described score, which did not include the presence of diabetes or
previously in this article, a second method of adjustment acuity of renal failure in its computation, did not explain
was performed using the total comorbidity score calcu- as much of the difference in survival of hemodialysis and
lated for each patient. In the groups defined by the first peritoneal dialysis patients as the alternative method.
dialysis modality received, the total comorbidity score Fenton et al obtained results similar to ours when they
was highly prognostic with a one-unit increase in the analyzed data from the Canadian Organ Replacement
score associated with a 25% increase in the mortality Registry using Cox regression to correct for covariables.
risk (P , 0.0001). When adjusted for the comorbidity When the initial modality of dialysis was used to define
score, the peritoneal dialysis/hemodialysis hazard ratios treatment groups, the peritoneal dialysis/hemodialysis
were 0.74 (95% CI, 0.58 to 0.94, P 5 0.01) at baseline, hazard ratio was 0.85 (95% CI, 0.78 to 0.92); there was
0.94 (95% CI, 0.74 to 1.19, P 5 NS) at three months, no survival advantage for either group when the mode
and 0.88 (95% CI, 0.68 to 1.13, P 5 NS) at six months. of dialysis in use at three months was used (hazard ratio
Figure 2 shows the peritoneal dialysis/hemodialysis haz- 0.95, 95% CI, 0.88 to 1.03) [2]. The primary technique
ard ratios calculated when the data is unadjusted, ad- used by Fenton et al, however, was Poisson regression.
justed for individual comorbidity variables, and adjusted Their analysis yielded a peritoneal dialysis/hemodialysis
for the total comorbidity score. There was no survival mortality rate ratio of 0.73 (95% CI, 0.67 to 0.78), which
advantage for either modality in any major subgroups was lower than that obtained by a similar analysis in our
defined by age, sex, or diabetic status (data not shown). study (rate ratio 0.88, 95% CI, 0.70 to 1.09) [2]. This
A high proportion of hemodialysis and peritoneal dial- may be partly explained by the fact that acute onset of
ysis patients underwent at least one switch in their mod- renal failure, a risk factor for mortality that is more
ality of dialysis treatment within the study period (Table prevalent in hemodialysis patients, was not included as
2). In the baseline groups, 25.4% of hemodialysis and a covariable the analysis by Fenton et al. It is not clear,
however, why a similar discrepancy in the results of Cox31.9% of HD patients ultimately switched therapy. Pa-
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Table 4. Mortality rate ratios, adjusted with Poisson regression (95% CI)
Factor Baseline Month 3 Month 6
Peritoneal dialysis vs. hemodialysis 0.88 (0.70–1.09) 0.84 (0.66–1.08) 0.80 (0.61–1.05)
NS NS P50.1
Age . median 2.09 (1.64–2.68) 1.88 (1.43–2.44) 1.78 (1.34–2.37)
P,0.0001 P,0.001 P50.0001
Male gender 1.00 (0.80–1.26) 1.01 (0.79–1.30) 1.09 (0.83–1.43)
NS NS NS
Acute onset 1.70 (1.31–2.20) 1.56 (1.15–2.10) 1.36 (0.97–1.91)
P50.0001 P50.004 P50.08
Diabetes 1.31 (1.04–1.65) 1.50 (1.16–1.94) 1.69 (1.28–2.23)
P50.02 P50.002 P50.0002
Cardiac failure 1.55 (1.23–1.96) 1.38 (1.06–1.79) 1.36 (1.02–1.80)
P50.0002 P50.02 P50.03
Myocardial infarction 1.11 (0.85–1.44) 1.18 (0.87–1.59) 1.27 (0.92–1.75)
NS NS NS
Peripheral vascular disease 1.58 (1.21–2.04) 1.39 (1.03–1.88) 1.19 (0.85–1.66)
P50.0007 P50.03 NS
Malignancy 2.30 (1.43–3.72) 2.17 (1.21–3.89) 2.04 (1.04–4.00)
P50.0006 P50.009 P50.04
Note: Results represent three separate analyses, starting at baseline, 3, and 6 months. NS is difference not statistically significant.
regression and Poisson regression was not observed in with peritoneal dialysis versus hemodialysis, with most
studies showing more comorbid illness in the formerthe current study.
Bloembergen et al had previously reported a 19% group [9, 11, 12]. The majority of studies, however, con-
sidered only the presence or absence of a given diseasehigher risk of death in patients treated with peritoneal
dialysis relative to hemodialysis using the U.S. Renal and contained no data on the severity of illness. Unlike
many previous studies, our study also considered theData System database [5]. This study was based on preva-
lent patient data. Since the 1989 to 1991 cohort, however, effect of acuity of onset of renal failure on subsequent
mortality in the study cohort, a factor that may be associ-incident patients have been included in U.S. Renal Data
System reports. When Vonesh and Moran analyzed this ated with a higher risk of death [19, 20]. As expected, a
much higher proportion of patients receiving hemodialy-data, they did not identify any increased risk of death for
patients treated with either modality, although subgroup sis as the first treatment had acute or acute-on-chronic
onset of renal failure compared with those initiallyanalysis suggested that younger diabetics on peritoneal
dialysis do better and older diabetics on peritoneal dial- treated with peritoneal dialysis. Acute onset of renal
failure imparted a higher risk of mortality at baselineysis do worse compared with their hemodialysis counter-
parts [1]. In another recent study of incident Medicare and three months, although this effect was no longer
statistically significant by six months. This suggests thatpatients surviving for at least 90 days, Collins et al re-
ported that nondiabetic patients treated with peritoneal although acuity of onset is a risk factor primarily for
early death, it is still an important covariable at 90 daysdialysis had a significantly lower risk of death compared
with those treated with hemodialysis. Diabetic patients after starting dialysis, the time point considered in many
epidemiologic studies as the treatment assignment date.on peritoneal dialysis and hemodialysis patients had sim-
ilar survival rates, with the exception of females older Other advantages of the current study lie in the fact
that the 11 centers represent a broad national samplethan 55 years, who had a 16% higher risk of death if they
were in the peritoneal dialysis group (abstract; Collins et and the cohort assembly period was relatively brief, min-
imizing the potential effects of changing dialysis technol-al, J Am Soc Nephrol 9:204A, 1998).
A major advantage of the current study lies in the ogy and techniques over time.
Because this study is not a randomized trial, there areextent of comorbidity data that has been collected. In a
nonrandomized observational study of two treatments, obviously many differences contributing to selection bias
in dialysis modality choice that cannot be adjusted for.selection bias is an extremely important consideration.
In the cohort used for the current study, detailed data Differences in education, socioeconomic status, family
supports, and patient attitudes are examples of variableson the presence and severity of illness were rigorously
collected in a prospective manner. In addition, a comor- that likely influence patient outcomes, but that are not
accounted for in our study. Also, the current study wasbidity score that has been previously validated and
shown to be prognostic was computed and used in sepa- not designed to investigate the influence of dialysis ade-
quacy or compliance on patient outcomes. Data per-rate multivariate analyses. Many previous studies have
shown an imbalance in comorbidity in patients treated taining to this were not systematically collected as part
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Report on dialysis and transplantation treatment from the Austra-of the study protocol. Even if adequacy data were avail-
lia and New Zealand Dialysis and Transplant Registry. Am J Kid-
able, it would not be a simple matter to compare dialysis ney Dis 25:165–175, 1995
5. Bloembergen W, Port FK, Mauger EA, Wolfe RA: A compari-dosage data for peritoneal dialysis and hemodialysis pa-
son of mortality between patients treated with hemodialysis andtients given the fundamental differences in solute clear-
peritoneal dialysis. J Am Soc Nephrol 6:177–183, 1995
ance and adequacy measurement. 6. Foley RN, Parfrey PS, Harnett JD, Kent GM, O’Dea R, Murray
DC, Barre` PE: Mode of dialysis therapy and mortality in end-Based on the results of this study, we conclude that:
stage renal disease. J Am Soc Nephrol 9:267–276, 1998(1) the apparent survival advantage of peritoneal dialysis
7. Charytan C, Spinowitz BS, Galler M: A comparative study of
is due to lower comorbidity and a lower burden of acute continuous ambulatory peritoneal dialysis and center hemodialysis:
Efficacy, complications, and outcome in the treatment of end-stageonset end-stage renal disease at the inception of dialysis
renal disease. Arch Intern Med 146:1138–1143, 1986therapy; and (2) hemodialysis and peritoneal dialysis, as
8. Gokal R, Jakubowski C, King J, Hunt L, Bogle S, Baillod R,
practiced in Canada in the 1990s, are associated with Marsh F, Ogg C, Oliver D, Ward M, Wilkinson R: Outcome
in patients on continuous ambulatory peritoneal dialysis and hemo-similar overall survival rates. Whether unmeasured com-
dialysis: 4-Year analysis of a prospective multicenter study. Lancetorbidity can explain the differences in survival found
2:1105–1109, 1987
in previous studies is not clear. Alternatively, it is pos- 9. Burton PR, Walls J: Selection-adjusted comparison of life expec-
tancy of patients on continuous ambulatory peritoneal dialysis,sible that advances in peritoneal dialysis technology or
hemodialysis, and renal transplantation. Lancet 1:1115–1119, 1987changes in the way peritoneal dialysis is prescribed have
10. Wolfe RA, Port FK, Hawthorne VN, Guir KE: A comparison
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